{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:04:10Z","timestamp":1787238250930,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Muscarinic agonists are indicated for the treatment of many conditions including ileus, urinary retention, glaucoma, and Sj\u00f6gren\u2019s syndrome. Due to their lack of tissue specificity, these drugs can lead to undesirable side effects at off-target sites and may be potentiated by supplements that impact the half-life of these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 58-year-old Caucasian female with history of Sj\u00f6gren\u2019s syndrome, who was being managed with cevimeline, presented to the primary care office with reported hyperhidrosis, malaise, nausea, and tachycardia. She reported taking an herbal supplement containing\n                      <jats:italic>B.\u00a0monnieri<\/jats:italic>\n                      and phosphatidylserine the previous night. It has been previously demonstrated that\n                      <jats:italic>B.\u00a0monnieri<\/jats:italic>\n                      alters cytochrome P450 enzymes. Electrocardiogram showed no acute ST\u2013T changes. Clinical improvement occurred with hydration and discontinuation of the supplement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To our knowledge, there has only been one other documented cevimeline overdose, and it was not associated with an herbal supplementation interaction. Physicians should actively elicit herbal supplement information from patients to anticipate possible drug\u2013herb interactions. An additional consideration of clinical relevance is the known genetic variability that may affect drug responsiveness due to differences in metabolism and half-life of drugs that arise from common genetic variants of cytochrome P450 genes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-022-03479-4","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:03:24Z","timestamp":1656443004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Blake","family":"Acquarulo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1760-9678","authenticated-orcid":false,"given":"Carolyn M.","family":"Macica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"126 Suppl 1","key":"3479_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/eos.12536","volume":"01","author":"R Jonsson","year":"2018","unstructured":"Jonsson R, Brokstad KA, Jonsson MV, Delaleu N, Skarstein K. Current concepts on Sjogren\u2019s syndrome\u2014classification criteria and biomarkers. Eur J Oral Sci. 2018;01(126 Suppl 1):37\u201348.","journal-title":"Eur J Oral Sci"},{"key":"3479_CR2","first-page":"247","volume":"6","author":"R Patel","year":"2014","unstructured":"Patel R, Shahane A. The epidemiology of Sjogren\u2019s syndrome. Clin Epidemiol. 2014;6:247\u201355.","journal-title":"Clin Epidemiol"},{"issue":"5","key":"3479_CR3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1097\/BOR.0000000000000622","volume":"31","author":"M Maslinska","year":"2019","unstructured":"Maslinska M. The role of Epstein-Barr virus infection in primary Sjogren\u2019s syndrome. Curr Opin Rheumatol. 2019;31(5):475\u201383.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"3479_CR4","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-021-23472-7","volume":"12","author":"P Soret","year":"2021","unstructured":"Soret P, Le Dantec C, Desvaux E, Foulquier N, Chassagnol B, Hubert S, et al. A new molecular classification to drive precision treatment strategies in primary Sjogren\u2019s syndrome. Nat Commun. 2021;12(1):3523.","journal-title":"Nat Commun"},{"issue":"12","key":"3479_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2165\/00003495-200868120-00006","volume":"68","author":"J Weber","year":"2008","unstructured":"Weber J, Keating GM. Cevimeline. Drugs. 2008;68(12):1691\u20138.","journal-title":"Drugs"},{"key":"3479_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/978-3-319-43806-1_2","volume-title":"Toxicology of herbal products","author":"J Sendker","year":"2017","unstructured":"Sendker J, Sheridan H. History and current status of herbal medicines. In: Pelkonen O, Duez P, Vuorela PM, Vuorela H, editors. Toxicology of herbal products. Cham: Springer International Publishing; 2017. p. 11\u201327."},{"issue":"4","key":"3479_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/rej.2013.1431","volume":"16","author":"S Aguiar","year":"2013","unstructured":"Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313\u201326.","journal-title":"Rejuvenation Res"},{"issue":"5","key":"3479_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0197-4580(87)90034-0","volume":"8","author":"MG Vannucchi","year":"1987","unstructured":"Vannucchi MG, Pepeu G. Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats. Neurobiol Aging. 1987;8(5):403\u20137.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"3479_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13181-010-0112-8","volume":"7","author":"B Voskoboynik","year":"2011","unstructured":"Voskoboynik B, Babu K, Hack JB. Cevimeline (Evoxac (R)) overdose. J Med Toxicol. 2011;7(1):57\u20139.","journal-title":"J Med Toxicol"},{"issue":"2","key":"3479_CR10","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.3390\/molecules19022588","volume":"19","author":"S Ramasamy","year":"2014","unstructured":"Ramasamy S, Kiew LV, Chung LY. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 2014;19(2):2588\u2013601.","journal-title":"Molecules"},{"issue":"3","key":"3479_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563\u201372.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3479_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.ackd.2019.08.003","volume":"27","author":"E Charen","year":"2020","unstructured":"Charen E, Harbord N. Toxicity of Herbs, Vitamins, and Supplements. Adv Chronic Kidney Dis. 2020;27(1):67\u201371.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"3479_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0002-9343(97)00397-5","volume":"104","author":"E Ernst","year":"1998","unstructured":"Ernst E. Harmless herbs? A review of the recent literature. Am J Med. 1998;104(2):170\u20138.","journal-title":"Am J Med"},{"issue":"10","key":"3479_CR14","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1089\/acm.2008.0290","volume":"14","author":"DH Mehta","year":"2008","unstructured":"Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med. 2008;14(10):1263\u20139.","journal-title":"J Altern Complement Med"},{"issue":"2","key":"3479_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1370\/afm.947","volume":"7","author":"BM Shelley","year":"2009","unstructured":"Shelley BM, Sussman AL, Williams RL, Segal AR, Crabtree BF. \u2018They don\u2019t ask me so I don\u2019t tell them\u2019: patient-clinician communication about traditional, complementary, and alternative medicine. Ann Fam Med. 2009;7(2):139\u201347.","journal-title":"Ann Fam Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03479-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:04:11Z","timestamp":1656443051000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03479-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3479"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03479-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"12 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Exemption status granted from the Institutional Review Board at Quinnipiac University (protocol #00322)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest regarding the publication of this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}